March 11, 2015.
The overall output of the Japanese drug industry measured by expected peak sales potential of newly National Health Insurance (NHI)-reimbursed drugs surged to $34 billion between 2010-2014, up from $16.9 billion during 2005-2009, according to Evaluate’s new report, Japan Sales, Volume, Pricing 2015. Highlights of the report include
The full version of the report can be downloaded at
www.evaluategroup.com/JapanSalesVolumePricing2015
.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.